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Abstract
Objective
To determine which of four Dixon image types [in-phase (IP), out-of-phase (OP), fat only
(FO) and water-only (WO)] is most sensitive for detecting multiple myeloma (MM) focal
lesions on whole body MRI (WB-MRI) images.
Methods
Thirty patients with clinically-suspected MM underwent WB-MRI at 3 Tesla. Unenhanced IP,
OP, FO and WO Dixon images were generated and read by four radiologists. On each
image type, each radiologist identified and labelled all visible myeloma lesions in the bony
pelvis. Each identified lesion was compared with a reference standard consisting of pre- and
post-contrast Dixon and diffusion weighted imaging (read by a further consultant radiologist)
to determine whether the lesion was truly positive. Lesion count, true positives, sensitivity,
and positive predictive value were compared across the four Dixon image types.
Results
Lesion count, true positives, sensitivity and confidence scores were all significantly higher
on FO images than on IP images (p>0.05).
Discussion
FO images are more sensitive than other Dixon image types for MM focal lesions, and
should be preferentially read by radiologists to improve diagnostic accuracy and reporting
efficiency.
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Introduction
In recent years, whole body-MRI (WB-MRI) has emerged as a valuable tool for assessing disease
activity in multiple myeloma (MM).[1–5] MRI is a key component of the Durie-Salmon PLUS
staging system[6], and the number of lesions identified on MRI correlates closely with mortal-
ity.[7] As a result, WB-MRI is developing into a first-line imaging modality in MM.[8,9]
The two major obstacles for widespread use of WB-MRI are cost and long scan times. It is
therefore important to maximise diagnostic value but minimise acquisition time, particularly for
MM patients who may be frail and in pain. To make best use of the available scan time, WB-MRI
protocols typically include both anatomical imaging (for assessment of morphology, fractures and
spinal cord compression[10,11]) and functional imaging (for assessing cellularity and perfusion
[5,11–13]). However, imaging protocols vary substantially between centres: anatomical imaging
may use T1-weighted or T2-weighted images (or a combination), and may implement spin echo-
or gradient echo-based sequences.[14] When choosing sequences, considerations include image
quality, acquisition time, the cost of data acquisition and storage, and interpretation time.
Recently, gradient echo-based Dixon MRI has been used for anatomical WB-MRI in MM
[5,14,15], and has several advantages over conventional T1- or T2-weighted imaging. Dixon
MRI enables the generation of four separate image types: in-phase (IP), out-of-phase (OP),
water-only (WO) and fat-only (FO). Acquisition times are similar to those for conventional
gradient echo imaging and shorter than for spin echo imaging.[15,16] When reporting, the IP
images can be viewed in a similar fashion to conventional T1-weighted images, whilst water
and fat can be separately evaluated on WO and FO images.
However, it is uncertain whether the ‘additional’ images (OP, WO and FO) offer any addi-
tional diagnostic information compared to IP imaging alone, and if so which image type is
optimal for reading. Therefore, the best approach to reporting WB-MRI is unclear: it is uncer-
tain whether reviewing the IP images alone is sufficient, or whether the additional images pro-
vide additional information. Clarifying this issue could improve the accuracy of disease
staging and also increase reporting efficiency—radiologists could begin their read by reviewing
the most diagnostically-useful scans. Furthermore, reconstructing and storing the additional
images would only be justified if they provided additional diagnostic information.
In this study, we aimed to evaluate radiologists’ diagnostic accuracy for detecting focal
lesions on each of the four Dixon image types, using post-contrast and diffusion images as a
reference standard. We hypothesised that sensitivity would be improved by using FO and WO
images compared to IP images.
Materials and methods
Subjects
This prospective study was performed with institutional review board approval (Research Eth-
ics Committee reference 12/LO/0428). All patients gave written informed consent.
Thirty patients (13 males and 17 females, median age 55, age range 36–82) with clinically
suspected symptomatic multiple myeloma were prospectively enrolled between June 2012 and
September 2014. Patients were excluded if they had a history of previous. malignancy or previ-
ous chemotherapy/radiotherapy, estimated GFR < 50 mL/min/1.73 m2, were unable to given
informed consent or had a contraindication to MRI scanning. Further assessment showed that
26 out of 30 had MM, one had smoldering MM, two a had solitary plasmocytoma, and one
had monoclonal gammopathy of uncertain significance. For each patient, clinical and bio-
chemical parameters were recorded as shown in Table 1. Baseline interphase fluorescence in
situ hybridisation (FISH) was performed on CD138-selected plasma cells from bone marrow
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samples, using probes for IGH translocations t(4:14), t(11;14) and t(14;16), del(17p), del(13)
and 1p-/1q+ [17]. Genetic risk was determined according to International Myeloma Working
Group recommendations [18].
Acquisition
All subjects underwent WB-MRI imaging on a 3.0T wide-bore system (Ingenia; Phillips
Healthcare, Best, Netherlands) using two anterior surface coils, a head coil and an integrated
posterior coil. The WB-MRI protocol included coronal pre- and post-contrast modified Dixon
(Dixon) acquisitions from which fat and water images and calculated in and out of phase
images were reconstructed on the scanner using a two-point method[19] (TR 3.0ms, TE 1.02–
18, flip angle 15˚, slice thickness 5mm, pixel bandwidth 1992Hz, acquisition matrix 196 x 238,
SENSE factor 2, number of slice 120) in addition to diffusion and post-contrast imaging cover-
ing vertex to toe using ten contiguous anatomical stations (Table 2). The coronal images were
‘stitched’ together and presented as a head-to-toe whole body image to the reader; the images
were then magnified according to the reader’s preference for specific analysis of the pelvis.
Image assessment
The individual sets of pre-contrast Dixon images were randomised and read by four consul-
tant radiologists, who each had between five and fifteen years of specialist expertise in
Table 1. Patient demographics, disease parameters and treatment. ISS, international staging system;
DS-PLUS, PAD, bortezomib, doxorubicin, dexamethasone; CVD, cyclophosphamide, bortezomib, dexameth-
asone; VTD, bortezomib, thalidomide, bortezomib.dexamethasone; MPV, melphalan, prednisolone,
bortezomib.
Patient characteristics Number or median (range)
Age (years) 56 (36–80)
Chain isotype
IgG 17
IgA 5
Light chain 4
MGUS 1
Solitary plasmacytoma 2
Smoldering MM 1
ISS stage
I 13
II 13
III 4
Induction regiment
PAD 18
CVD 3
VTD 5
MPV 2
Bone marrow percentage plasma cells 65 (0–90)
Beta-2 microglobulin (mg/l) 3.3 (1.3–11.3)
Albumin (g/l) 40 (30–53)
Creatinine 56 (77.5–105)
Genetic risk group
Low/Standard risk 17
High risk 9
https://doi.org/10.1371/journal.pone.0180562.t001
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oncological MR imaging. All readers were blinded to clinical data and diagnosis. On each
image set, each radiologist was asked to count the number of myeloma lesions present in the
bony pelvis (pubis, ischium, ilium and sacrum) and to label these lesions on the images (up to
a maximum of 20). If the disease was diffuse or there were over 20 lesions, the patient was
assigned a lesion count of 20. Additionally, the radiologists were asked to provide a confidence
score based on their degree of certainty that there were myeloma lesions in the pelvis on a
4-point Likert scale (1-no lesions, 2-indeterminate lesions, 3-likely myeloma lesions, 4-very
likely myeloma lesions). After scoring, each labelled lesion was compared to a reference stan-
dard consisting of diffusion-weighted, pre- and post-contrast Dixon imaging, which had been
evaluated by a further consultant radiologist with over 20 years of experience in myeloma and
MR imaging. On the reference imaging, all lesions demonstrating abnormal marrow signal
compared to background marrow (i.e. hypointense on IP and FO images, and hyperintense on
WO images) and which showed contrast enhancement or restricted diffusion were assigned as
myeloma lesions and labelled on the images. For the reference standard, no maximum lesion
count was used (i.e. all lesions were labelled) to ensure that all lesions on the IP, OP, FO and
WO Dixon images could be compared directly to a reference lesion. Using the reference stan-
dard imaging, we also recorded whether patients had focal or diffuse disease (the diffuse cate-
gory included patients with focal-on-diffuse infiltration).
For each Dixon image set, we compared each lesion with the reference standard to deter-
mine the number of per-set true positive lesions (TP), false positive lesions (FP) (i.e. those that
were incorrectly identified as lesions); and false negative lesions (FN) (these were the ‘refer-
ence-standard lesions’ which were not identified). For each Dixon image type (30 sets per
type), we determined the mean per-set lesion count, sensitivity (TP/TP+FN), positive predic-
tive value (TP/TP + FP) and mean confidence score.
Design and statistics
A summary of the study design is given in Fig 1. To account for clustering within the data, for
each lesion detection metric (lesion count, sensitivity, positive predictive value and mean con-
fidence score), values were compared across the four Dixon image types using a multilevel
mixed-effects linear regression model, performed using Stata [Stata IC Version 14.1, College
Table 2. Sequence parameters.
Sequence Parameters
Parameters Dixon
(pre and post contrast)
DWI (b0, 100, 300, 1000 s/mm2)
Imaging Plane Coronal Transverse
Sequence type Gradient echo Single-shot spin echo with echo planar readout
Echo time (ms) 1.02/1.8 71
Repetition time (ms) 3 6371
Field of View (mm x mm) 502 x 300 500 x 306
Voxel size (mm x mm) 2.1 x 2.1 4 x 4.2
Number of Slices 120 40
Slice Thickness (mm) 5 5
Acquisition Matrix 144 x 238 124 x 72
ETL 2 39
Acceleration factor (SENSE) 2 2.5
Pixel Bandwidth (Hz) 1992 3369
Scan time (s) 17 152
https://doi.org/10.1371/journal.pone.0180562.t002
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Station, USA]. Image type (i.e. IP, OP, FO or WO) was used as the predictor variable, and the
value of the specific lesion detection metric being analysed (i.e. lesion count, sensitivity, posi-
tive predictive value or mean confidence score) was used as the outcome variable. Data were
clustered at the level of ‘subject’ (patient) and ‘observer’ (radiologist). This analysis was
repeated for the subgroup of patients who had diffuse disease (as determined by the reference
standard assessment), and for the subgroup of patients with focal disease.
Percent contrast and contrast-to-noise ratio
Percent contrast and contrast-to-noise ratio (CNR) were calculated using a previously
described method [15]. Specifically, in patients with at least three focal lesions greater than
3mm in diameter, circular regions of interest (ROIs) were placed on the three largest focal
myeloma lesions, and three further ROIs were placed in areas of bone marrow without focal
lesions in the sacrum and iliac bones.
Percent contrast was calculated as:
Percent Contrast ¼
ðSa   SbÞ
ðSa þ SbÞ
Fig 1. Study design.
https://doi.org/10.1371/journal.pone.0180562.g001
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where Sa is the mean signal intensity of myeloma lesions and Sb is the background marrow sig-
nal intensity.
Similarly, CNR was calculated as:
CNR ¼
jSa   Sbjffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðSasd þ SbsdÞ=2
p
where Sasd and Sbsd are the mean within-ROI standard deviation values for myeloma lesions
and background marrow respectively. A one-way analysis of variance (ANOVA) with a post-
hoc Tukey Kramer multiple comparison test was used to compare percent contrast and CNR
between image series.
Results
Four radiologists read four image series for each of 30 patients (120 image series per radiolo-
gist), and identified 610, 955, 549 and 734 lesions respectively compared to 1560 reference
lesions. An example of a focal lesion, as shown on the four Dixon image types, is given in Fig 2.
A summary of the mean lesion count, true positives, sensitivity, positive predictive value and
confidence score for each of the four image types is given in Table 3; these values are also
shown graphically in Fig 3. The results of the regression analysis including confidence intervals
are also provided in Table 3.
Lesion count and true positives
The mean lesion counts for each image type (averaged over all patients and all four radiolo-
gists) were 5.2 for IP, 5.8 for OP, 7.0 for FO and 5.7 for WO. Significantly more lesions were
identified on the FO images than on the IP images (p = 0.006), but there was no significant dif-
ference between OP and IP images (p = 0.364) or WO and IP images (p = 0.504).
Of the identified lesions, the mean number of true positives was 4.9 for IP, 4.6 for OP, 6.5
for FO and 5.1 for WO. Significantly more true positive lesions were identified on the FO
Fig 2. Examples of focal MM lesions. There is a large focal lesion in the right ischium (solid arrow) and a
smaller lesion in the right ilium (dashed arrow); both lesions are shown on unenhanced Dixon images (IP, OP,
WO and FO) and on the reference images (consisting of DWI and post-contrast). The smaller lesion is less
conspicuous on the IP and OP images than on the FO and WO images. *DWI was acquired in the axial plane;
the smaller of the two lesions (in the right ilium) is again marked with a dashed arrow.
https://doi.org/10.1371/journal.pone.0180562.g002
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images than on the IP images (p = 0.008), but there was no significant difference in true posi-
tives between OP and IP images (p = 0.633) or WO and IP images (p = 0.702).
Sensitivity and positive predictive value
The mean sensitivity for each image type was 0.34 for IP, 0.32 for OP, 0.42 for FO and 0.36 for
WO. Sensitivity was significantly higher on the FO images than on the IP images (p = 0.023),
but there was no significant difference between OP and IP images (p = 0.696) or between WO
and IP images (p = 0.590).
The mean positive predictive values were 0.86 for IP, 0.67 for OP, 0.81 for FO and 0.82 for
WO. There was no significant difference in PPV for FO compared to IP (p = 0.146) or WO
compared to IP (p = 0.617). However, positive predictive values were significantly poorer on
OP images than on IP images (p = 0.000).
Table 3. Results of regression analysis (n = 30).
Lesion Count
Image type Mean Difference in means (95% CI) p-value
IP 5.2 Baseline -
OP 5.8 +0.60 (-0.70 to +1.90) 0.364
FO 7.0 +1.83 (+0.53 to +3.12) 0.006
WO 5.7 +0.44 (-0.85 to +1.74) 0.504
True positives
Image type Mean Difference in means (95% CI) p-value
IP 4.9 Baseline -
OP 4.6 -0.29 (-1.48 to +0.90) 0.633
FO 6.5 +1.63 (-1.48 to +0.90) 0.008
WO 5.1 +0.23 (-0.96 to +1.43) 0.702
Sensitivity
Image type Mean Difference in means (95% CI) p-value
IP 0.34 Baseline -
OP 0.32 -0.02 (-0.09 to +0.06) 0.696
FO 0.42 +0.09 (+0.01 to +0.16) 0.023
WO 0.36 +0.02 (-0.06 to +0.10) 0.590
Positive predictive value
Image type Mean Difference in means (95% CI) p-value
IP 0.86 Baseline -
OP 0.67 -0.17 (-0.24 to -0.10) 0.000
FO 0.81 -0.05 (-0.12 to +0.02) 0.146
WO 0.82 -0.02 (-0.09 to + 0.05) 0.617
Confidence Score (/4)
Image type Mean Difference in means (95% CI) p-value
IP 2.48 Baseline -
OP 2.65 +0.18 (-0.01 to +0.36) 0.063
FO 2.73 +0.26 (+0.07 to +0.44) 0.006
WO 2.68 +0.20 (+0.16 to + 0.38) 0.033
Lesion count, true positives, sensitivity, positive predictive value and confidence were compared between
the four image types, using the in phase images as the baseline. Regression analyses used image type were
used as the predictor variable, and lesion count/TP/sensitivity/confidence were used as the outcome
variable. Mean values were calculated by the regression analysis, and were equal to means calculated
manually from all patients and all four radiologists.
https://doi.org/10.1371/journal.pone.0180562.t003
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Confidence score
The mean confidence scores were 2.48 for IP, 2.65 for OP, 2.73 for FO and 2.68 for WO (1-no
lesions, 2-indeterminate lesions, 3-likely myeloma lesions, 4-very likely myeloma lesions).
Confidence scores were higher on all three image types than on the IP images (OP compared
to IP: p = 0.063, FO compared to IP: p = 0.006, WO compared to IP: p = 0.033).
Sub-group analysis
Of 30 patients, there were 23 patients in the focal disease group (this included the two patients
with solitary plasmacytoma) and six patients in the diffuse disease group. True positives, sensi-
tivity and PPV for focal and diffuse groups are given in Table 4 and Table 5 respectively.
In the focal disease group, true positives and sensitivity were significantly higher in the FO
group than in the IP group (p = 0.008 and 0.037 respectively). There was no significant differ-
ence in PPV between IP and FO groups (p = 0.516). The OP images performed significantly
less well than IP images in terms of PPV (p = 0.000).
In the diffuse disease group, there were no significant differences between FO and IP groups
in terms of true positives, sensitivity or PPV (p = 0.483, p = 0.349 and p = 0.113 respectively).
PPV was again significantly poorer on the OP images than on the IP images (p = 0.004).
True positives and sensitivity were higher for the focal disease group (sensitivity on FO
images was 0.29 in the diffuse group and 0.46 in the focal group), although these groups were
not formally compared.
Percent contrast and contrast-to-noise ratio
Comparison of percent contrast and CNR between groups is demonstrated in Fig 4. Percent
contrast was highest in the FO group (the values for each image type were, IP: 8.1, OP: 17, FO:
Fig 3. Lesion count, sensitivity, positive predictive value (PPV) and confidence for each Dixon image
type. Individual observers are shown in colour (see legend), and the mean value across all four observers is
shown in black. Error bars indicate the 95% confidence interval.
https://doi.org/10.1371/journal.pone.0180562.g003
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30 and WO: 4.5), and was significantly higher for FO images than for IP images (p = 0.003).
There was no significant difference between OP and IP images, or between WO and IP
images.
Table 5. Results of regression analysis for the diffuse disease group (n = 6).
True positives
Image type Mean Difference in means (95% CI) p-value
IP 4.0 Baseline -
OP 2.9 -1.13 (-4.0 to +1.8) 0.449
FO 5.0 +1.04 (-1.9 to +4.0) 0.483
WO 4.7 +0.71 (-2.2 to +3.6) 0.634
Sensitivity
Image type Mean Difference in means (95% CI) p-value
IP 0.22 Baseline -
OP 0.15 -0.07 (-0.23 to +0.09) 0.398
FO 0.29 +0.08 (-0.09 to +0.24) 0.349
WO 0.25 +0.03 (-0.12 to +0.19) 0.674
Positive predictive value
Image type Mean Difference in means (95% CI) p-value
IP 0.85 Baseline -
OP 0.58 -0.27 (-0.46 to -0.09) 0.004
FO 0.65 -0.15 (-0.33 to +0.035) 0.113
WO 0.85 -0.06 (-0.26 to +0.13) 0.522
True positives, sensitivity, positive predictive value and confidence are compared across the four image
types, using the in phase images as the baseline.
https://doi.org/10.1371/journal.pone.0180562.t005
Table 4. Results of regression analysis for the focal lesion group alone (n = 23).
True positives
Image type Mean Difference in means (95% CI) p-value
IP 5.1 Baseline -
OP 5.0 -0.08 (-1.38 to +1.21) 0.900
FO 6.8 +1.77 (+0.47 to +3.07) 0.008
WO 5.2 +0.11 (-1.19 to +1.42) 0.863
Sensitivity
Image type Mean Difference in means (95% CI) p-value
IP 0.37 Baseline -
OP 0.36 -0.00 (-0.09 to +0.08) 0.976
FO 0.46 +0.09 (-0.01 to +0.18) 0.037
WO 0.38 +0.02 (-0.07 to +0.10) 0.689
Positive predictive value
Image type Mean Difference in means (95% CI) p-value
IP 0.79 Baseline -
OP 0.63 -0.14 (-0.21 to -0.07) 0.000
FO 0.78 -0.02 (-0.09 to +0.05) 0.516
WO 0.72 -0.00 (-0.08 to +0.07) 0.936
True positives, sensitivity, positive predictive value and confidence are compared across the four image
types, using the in phase images as the baseline.
https://doi.org/10.1371/journal.pone.0180562.t004
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Contrast to noise ratio was also highest in the FO group (the values for each image type
were, IP: 3.41, OP: 3.34, FO: 5.57 and WO: 5.04). However, was no significant difference in
CNR between groups.
Discussion
In this study, lesion counts, true positive counts, sensitivity, positive predictive value and
reader confidence were compared across the four Dixon images types. We have shown that
FO images are superior to other image types and in particular IP images in terms of lesion
counts, true positives, sensitivity and confidence. Furthermore, our data suggest that focal
lesions demonstrate greater contrast compared to background marrow on FO images than on
IP images, which may account for the superior sensitivity of FO images. The positive predictive
values for FO images were similar to those for IP and WO images and higher than those for
OP images, suggesting that the increase in sensitivity reflects a true increase in lesion conspicu-
ity rather than a lower reader threshold for lesion identification. The use of FO images offered
the greatest advantage for patients with focal lesions, but also provided superior sensitivity in
patients with diffuse disease.
The superior performance of FO imaging could occur because myelomatous infiltration of
the bone marrow causes a proportionally greater reduction in marrow fat content than in
water content. Normal adult bone marrow typically consists of 50–90% fat[20–22] and infiltra-
tion with myeloma cells decreases fat content[13,23,24]; however, the increase in water content
may be relatively less because myeloma cells have an increased nuclear to cytoplasmic ratio.
[25] This suggestion is supported by the observation that focal lesions are more difficult to
detect in younger patients with cellular bone marrow imaging [26] or in myeloma patients
with a higher bone marrow cell percentage.[15]
To our knowledge, this is the first study comparing lesion detection rates on individual
Dixon images in patients with MM. A small number of studies have examined lesion contrast
in Dixon imaging compared to other sequences[15,27], but none of these have directly exam-
ined lesion detection rates by radiologists. This study suggests that the use Dixon imaging
improves diagnostic sensitivity and confidence compared to in phase T1-weighted gradient
Fig 4. Comparison of percent contrast and CNR between groups. The figures show the results of a post-
hoc multiple comparison test from a one-way ANOVA. Estimates of Percent Contrast and CNR are shown as
circles; the comparison intervals for each group are shown as solid lines. Percent contrast was significantly
higher on FO images than on IP images (p = 0.003).
https://doi.org/10.1371/journal.pone.0180562.g004
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echo imaging alone. We therefore argue that Dixon imaging should be used in preference to
T1-weighted imaging alone for anatomical WB-MRI in MM. Furthermore, radiologists should
specifically review the FO image type when reading WB-MRI in MM to increase diagnostic
yield and improve reporting efficiency.
The accuracy of lesion detection in MM directly impacts on assessment of disease burden
and therefore prognosis.[7] Walker et al. showed that patients with more than seven focal
lesions on WB-MRI had a five year survival of 55%, compared to 73% for those with no focal
lesions [7]. Moulopolos et al. similarly showed that radiological assessment of disease burden
could be used to separate patients into different survival categories.[28] In patients with only a
small number of lesions, poor diagnostic sensitivity could theoretically alter the diagnosis
itself–small volume disease could be missed altogether, or patients with a small number of
lesions (>1) could be incorrectly diagnosed with solitary plasmacytoma.
A limitation of this study is that our observations are confined to images generated using a
single Dixon sequence. It would be preferable to compare sensitivity and positive predictive
value across gradient echo (Dixon) and spin echo images including T1-weighted and STIR
images, to form a more definitive overall assessment of the optimal sequence. However, this
type of study would be difficult to perform in practice since acquiring conventional T1-
weighted spin echo images in addition to Dixon images would be extremely time consuming.
Furthermore, previous studies suggest that gradient echo imaging offers similar image quality
spin echo imaging in MM.[16]
The study is also limited by the nature of the scoring system used. In particular, the upper
limit of 20 for the lesion count means that we have not captured differences in the number of
lesions detected in patients with very high tumour load. However, the clinical importance of
these differences is doubtful and current staging systems do not differentiate between patients
with more than 20 lesions.[6,29] Our scoring system also penalises observers who fail to iden-
tify diffuse infiltration, leading to generally low sensitivity scores when compared to the refer-
ence standard.
Further work is required to examine the diagnostic utility of different MR sequences to
arrive at an optimised protocol for WB-MRI in MM. In particular, it would be useful to deter-
mine the extent to which DWI, post-contrast and pre-contrast Dixon imaging each contribute
to the overall interpretation of the WB-MRI scan. Careful assessment of the ‘value’ of each
sequence is essential if cost-effective, high volume whole body scanning is to be achieved.
High-value MRI is becoming an increasingly important goal for the imaging community[30],
and studies specifically examining the value of WB-MRI in MM will be essential for wide-
spread clinical implementation.
Conclusion
Fat-only Dixon images offer higher lesion detection rates compared to in-phase images alone
in multiple myeloma. We suggest that radiologists should preferentially review the fat-only
images when reading to improve diagnostic accuracy and reporting efficiency.
Supporting information
S1 File. Raw data showing lesion detection rates for the four Dixon image types. Lesion
counts, true positives, false positives, false negatives, sensitivity, PPV and confidence are pro-
vided for each of the image types, for each observer and each patient. Please refer to the Mate-
rials and Methods section for more information on data arrangement.
(XLSX)
Diagnostic utility of Dixon MRI in multiple myeloma
PLOS ONE | https://doi.org/10.1371/journal.pone.0180562 July 3, 2017 11 / 14
Author Contributions
Conceptualization: Timothy J. P. Bray, Saurabh Singh, Arash Latifoltojar, Andre Lopes, Sho-
nit Punwani, Margaret A. Hall-Craggs.
Data curation: Timothy J. P. Bray, Saurabh Singh, Arash Latifoltojar, Shonit Punwani, Marga-
ret A. Hall-Craggs.
Formal analysis: Timothy J. P. Bray, Saurabh Singh, Arash Latifoltojar, Kannan Rajesparan,
Farzana Rahman, Priya Narayanan, Sahar Naaseri, Shonit Punwani, Margaret A. Hall-
Craggs.
Funding acquisition: Shonit Punwani, Margaret A. Hall-Craggs.
Investigation: Timothy J. P. Bray, Kannan Rajesparan, Farzana Rahman, Priya Narayanan,
Sahar Naaseri, Alan Bainbridge, Margaret A. Hall-Craggs.
Methodology: Timothy J. P. Bray, Saurabh Singh, Arash Latifoltojar, Andre Lopes, Alan Bain-
bridge, Margaret A. Hall-Craggs.
Project administration: Alan Bainbridge, Shonit Punwani, Margaret A. Hall-Craggs.
Resources: Alan Bainbridge, Margaret A. Hall-Craggs.
Software: Timothy J. P. Bray, Saurabh Singh, Alan Bainbridge.
Supervision: Andre Lopes, Alan Bainbridge, Shonit Punwani, Margaret A. Hall-Craggs.
Visualization: Timothy J. P. Bray, Arash Latifoltojar, Margaret A. Hall-Craggs.
Writing – original draft: Timothy J. P. Bray, Saurabh Singh, Arash Latifoltojar, Andre Lopes,
Shonit Punwani, Margaret A. Hall-Craggs.
Writing – review & editing: Timothy J. P. Bray, Saurabh Singh, Kannan Rajesparan, Farzana
Rahman, Priya Narayanan, Sahar Naaseri, Andre Lopes, Alan Bainbridge, Shonit Punwani,
Margaret A. Hall-Craggs.
References
1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, mul-
tiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haema-
tol. 2003; 121(5):749–57. PMID: 12780789
2. Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma work-
ing group consensus statement and guidelines regarding the current role of imaging techniques in the
diagnosis and monitoring of multiple Myeloma. Leuk Off J Leuk Soc Am Leuk Res Fund, UK. 2009; 23
(9):1545–56.
3. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus
recommendations for standard investigative workup: Report of the International Myeloma Workshop
Consensus Panel 3. In: Blood. 2011. p. 4701–5.
4. Bird JM, Owen RG, D’Sa S, Snowden JA, Pratt G, Ashcroft J, et al. Guidelines for the diagnosis and
management of multiple myeloma 2011. Br J Haematol. 2011; 154(1):32–75. https://doi.org/10.1111/j.
1365-2141.2011.08573.x PMID: 21569004
5. Giles SL, Messiou C, Collins DJ, Morgan VA, Simpkin CJ, West S, et al. Whole-Body Diffusion-weighted
MR Imaging for Assessment of Treatment Response in Myeloma. Radiology [Internet]. 2014; 271
(3):131529. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24475858
6. Durie BGM, Kyle R a, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guide-
lines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol
J. 2003; 4:379–98. https://doi.org/10.1038/sj.thj.6200312 PMID: 14671610
7. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, et al. Magnetic resonance
imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007 Mar; 25(9):1121–
8. https://doi.org/10.1200/JCO.2006.08.5803 PMID: 17296972
Diagnostic utility of Dixon MRI in multiple myeloma
PLOS ONE | https://doi.org/10.1371/journal.pone.0180562 July 3, 2017 12 / 14
8. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Mye-
loma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;
15(12):e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5 PMID: 25439696
9. Excellence NI of H and C. Myeloma: diagnosis and management. NG35. 2016;(February).
10. Lecouvet FE, Vande Berg BC, Michaux L, Malghem J, Maldague BE, Jamart J, et al. Stage III multiple
myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology. 1998; 209
(3):653–60. https://doi.org/10.1148/radiology.209.3.9844655 PMID: 9844655
11. Lecouvet FE. Whole-Body MR Imaging: Musculoskeletal Applications. Radiology. 2016; 279(2):345–
65. https://doi.org/10.1148/radiol.2016142084 PMID: 27089188
12. Messiou C, Collins DJ, Morgan VA, Desouza NM. Optimising diffusion weighted MRI for imaging meta-
static and myeloma bone disease and assessing reproducibility. Eur Radiol. 2011; 21(8):1713–8.
https://doi.org/10.1007/s00330-011-2116-4 PMID: 21472473
13. Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Hae-
matol. 2012 Dec; 159(5):499–513. https://doi.org/10.1111/bjh.12007 PMID: 22881361
14. Dixon WT. Simple proton spectroscopic imaging. Radiology. 1984; 153(1):189–94. https://doi.org/10.
1148/radiology.153.1.6089263 PMID: 6089263
15. Takasu M, Tamura T, Kaichi Y, Tanitame K, Akiyama Y, Date S, et al. Magnetic resonance evaluation
of multiple myeloma at 3.0 Tesla: how do bone marrow plasma cell percentage and selection of proto-
cols affect lesion conspicuity? PLoS One. 2014 Jan; 9(1):e85931. https://doi.org/10.1371/journal.pone.
0085931 PMID: 24489680
16. Weckbach S, Michaely HJ, Stemmer A, Schoenberg SO, Dinter DJ. Comparison of a new whole-body
continuous-table-movement protocol versus a standard whole-body MR protocol for the assessment of
multiple myeloma. Eur Radiol. 2010 Dec; 20(12):2907–16. https://doi.org/10.1007/s00330-010-1865-9
PMID: 20574630
17. Smith D, Stephenson C, Percy L, Lach A, Chatters S, Kempski H, et al. Cohort analysis of FISH testing
of CD138+ cells in relapsed multiple myeloma: Implications for prognosis and choice of therapy. Br J
Haematol. 2015; 171(5):881–3. https://doi.org/10.1111/bjh.13446 PMID: 25899469
18. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple
myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group. Blood.
2016; 127(24):2955–62. https://doi.org/10.1182/blood-2016-01-631200 PMID: 27002115
19. Eggers H, Brendel B, Duijndam A, Herigault G. Dual-Echo Dixon Imaging with Flexible Choice of Echo
Times.
20. Karampinos DC, Melkus G, Baum T, Bauer JS, Rummeny EJ, Krug R. Bone marrow fat quantification
in the presence of trabecular bone: Initial comparison between water-fat imaging and single-voxel MRS.
Magn Reson Med. 2014; 71(3):1158–65. https://doi.org/10.1002/mrm.24775 PMID: 23657998
21. Li X, Kuo D, Schafer AL, Porzig A, Link TM, Black D, et al. Quantification of vertebral bone marrow fat
content using 3 Tesla MR spectroscopy: Reproducibility, vertebral variation, and applications in osteo-
porosis. J Magn Reson Imaging. 2011; 33(4):974–9. https://doi.org/10.1002/jmri.22489 PMID:
21448966
22. Liney GP, Bernard CP, Manton DJ, Turnbull LW, Langton CM. Age, gender, and skeletal variation in
bone marrow composition: A preliminary study at 3.0 Tesla. J Magn Reson Imaging. 2007; 26(3):787–
93. https://doi.org/10.1002/jmri.21072 PMID: 17729356
23. Takasu M, Tani C, Sakoda Y, Ishikawa M, Tanitame K, Date S, et al. Iterative decomposition of water
and fat with echo asymmetry and least-squares estimation (IDEAL) imaging of multiple myeloma: initial
clinical efficiency results. Eur Radiol [Internet]. 2012; 22(5):1114–21. Available from: http://www.ncbi.
nlm.nih.gov/pubmed/22138735 https://doi.org/10.1007/s00330-011-2351-8 PMID: 22138735
24. Takasu M, Kaichi Y, Tani C, Date S, Akiyama Y, Kuroda Y, et al. Iterative decomposition of water and
fat with echo asymmetry and least-squares estimation (IDEAL) magnetic resonance imaging as a bio-
marker for symptomatic multiple myeloma. PLoS One. 2015; 10(2):e0116842. https://doi.org/10.1371/
journal.pone.0116842 PMID: 25706753
25. D’Onofrio G, Zini G. Morphology of Blood Disorders. Morphology of Blood Disorders. 2014. 1–787 p.
26. Hillengass J, Weber M-A, Kilk K, Listl K, Wagner-Gund B, Hillengass M, et al. Prognostic significance of
whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia.
2014 Jan; 28(1):174–8. https://doi.org/10.1038/leu.2013.244 PMID: 23958921
27. Costelloe CM, Madewell JE, Kundra V, Harrell RK, Bassett RL, Ma J. Conspicuity of bone metastases
on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence. Magn Reson Imag-
ing. 2013 Jun; 31(5):669–75. https://doi.org/10.1016/j.mri.2012.10.017 PMID: 23290478
28. Moulopoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, et al. Prognostic sig-
nificance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple
Diagnostic utility of Dixon MRI in multiple myeloma
PLOS ONE | https://doi.org/10.1371/journal.pone.0180562 July 3, 2017 13 / 14
myeloma. Ann Oncol. 2005 Nov; 16(11):1824–8. https://doi.org/10.1093/annonc/mdi362 PMID:
16087694
29. Kyle RA, Child JA, Anderson K, Barlogie B, Bataille R, Bensinger W, et al. Criteria for the classification
of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International
Myeloma Working Group. Vol. 121, British Journal of Haematology. 2003. p. 749–57. PMID: 12780789
30. ISMRM. The MR Value Initiative [Internet]. Available from: http://www.ismrm.org/the-mr-value-initiative-
phase-1/
Diagnostic utility of Dixon MRI in multiple myeloma
PLOS ONE | https://doi.org/10.1371/journal.pone.0180562 July 3, 2017 14 / 14
